Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 2756 · Affordable Inhalers and Nebulizers Act of 2025 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

26 U.S.C. § 223 Health savings accounts

+2 −0Shown
More for 26 U.S.C. § 223
Read § 223Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 223(c)(2) of the Internal Revenue Code of 1986 is amended by adding at the end the following new subparagraph:(I) Safe harbor for absence of deductible for specified inhaler products.— For plan years beginning on or after January 1, 2026, a plan shall not fail to be treated as a high deductible health plan by reason of failing to have a deductible for specified inhaler products (as …

§ 223(c)Definitions and special rules(2)–(3)

Start of § 223 to (c)(2)(H) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(2)(H)(i)(i) (i)
available as individual coverage through an Exchange established under section 1311 or 1321 of the Patient Protection and Affordable Care Act, andavailable as individual coverage through an Exchange established under section 1311 or 1321 of the Patient Protection and Affordable Care Act, and
(2)(H)(ii)(ii) (ii)
described in subsection (d)(1)(A) or (e) of section 1302 of such Act.described in subsection (d)(1)(A) or (e) of section 1302 of such Act.
(2)(I)(I) [inserted: Safe harbor for absence of deductible for specified inhaler products.—]
[inserted: For plan years beginning on or after January 1, 2026, a plan shall not fail to be treated as a high deductible health plan by reason of failing to have a deductible for specified inhaler products (as defined in section 2799A–11 of the Public Health Service Act).]
(3)(3) Permitted insurance(3) Permitted insurance
The term “permitted insurance” means—The term “permitted insurance” means—
(3)(A)(A) (A)
insurance if substantially all of the coverage provided under such insurance relates to—insurance if substantially all of the coverage provided under such insurance relates to—

Rest of § 223 unchanged

26 U.S.C. § 9826 Coverage and cost-sharing requirements for specified inhaler products New section

+11 −0Shown
More for 26 U.S.C. § 9826
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:9826. Coverage and cost-sharing requirements for specified inhaler products (a) In general.— A group health plan shall provide benefits under such plan for all specified inhaler products and, with respect to such a product, may not— (1) apply any deductible; or (2) impose any cost-sharing requirement in excess of $15 per 30-day supply of such product. (b) Counting cost-Sharing towards deductible and out-of-Pocket maximum.— A group health plan shall count any cost-sharing requirement described in subsection (a)(2) incurred by a participant or beneficiary of such plan with respect to a specified inhaler product towards any out-of-pocket maximum and any deductible that, but for application of subsection (a), would have applied to such participant or beneficiary with respect to such product. (c) Specified inhaler product defined.— For purposes of this section, the term specified inhaler product means any maintenance or reliever or rescue inhalation drug (including inhalation aerosols, metered dose inhalers, dry powder inhalers, inhalation solutions, bronchodialators, and corticosteroids) with a medically accepted indication (as defined in section 1927(k)(6) of the Social Security Act (42 U.S.C. 13964–8(k)(6))) for the treatment of asthma or of chronic obstructive pulmonary disease. Such term includes any equipment used in the administration of such drug (such as masks and tubing, spacers, nebulizers, and valve-holding chambers)..

    The section already has a provision under this letter or number, so it would have two.

The Code already has a 26 U.S.C. § 9826, a different section added since this bill was written, so this would be a second section under that number.

§ 9826(a)–(c)

WhereMarkThe Code nowMarkAs the bill would leave it
§ 9826. [inserted: Coverage and cost-sharing requirements for specified inhaler products]
(a)(a) [inserted: In general.—]
[inserted: A group health plan shall provide benefits under such plan for all specified inhaler products and, with respect to such a product, may not—]
(a)(1)(1) [inserted: ]
[inserted: apply any deductible; or]
(a)(2)(2) [inserted: ]
[inserted: impose any cost-sharing requirement in excess of $15 per 30-day supply of such product.]
(b)(b) [inserted: Counting cost-Sharing towards deductible and out-of-Pocket maximum.—]
[inserted: A group health plan shall count any cost-sharing requirement described in subsection (a)(2) incurred by a participant or beneficiary of such plan with respect to a specified inhaler product towards any out-of-pocket maximum and any deductible that, but for application of subsection (a), would have applied to such participant or beneficiary with respect to such product.]
(c)(c) [inserted: Specified inhaler product defined.—]
[inserted: For purposes of this section, the term “specified inhaler product” means any maintenance or reliever or rescue inhalation drug (including inhalation aerosols, metered dose inhalers, dry powder inhalers, inhalation solutions, bronchodialators, and corticosteroids) with a medically accepted indication (as defined in section 1927(k)(6) of the Social Security Act (42 U.S.C. 13964–8(k)(6))) for the treatment of asthma or of chronic obstructive pulmonary disease. Such term includes any equipment used in the administration of such drug (such as masks and tubing, spacers, nebulizers, and valve-holding chambers).]

42 U.S.C. § 1395l Payment of benefits

+2 −22 of 4 shown
More for 42 U.S.C. § 1395l
Read § 1395lOnly this section
4 changes the bill asks for here, 2 carried out
  1. Not carried out:

    in clause (i), by inserting or (iii) after clause (ii); and

    The bill points to (S) in § 1395l(a)(1), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no level (S) under /us/usc/t42/s1395l/a/1
  2. Not carried out:

    by adding at the end the following new clause: and (iii) with respect to a specified inhaler product (as defined in section 2799A–11 of the Public Health Service Act) furnished on or after January 1, 2026, the amounts paid shall be 100 percent of the lesser of the actual charge or the payment amount established in section 1842(o) (or, if applicable, under section 1847, 1847A, or 1847B), less, per 30-day supply of such product, $15,; and

    The bill points to (S) in § 1395l(a)(1), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no level (S) under /us/usc/t42/s1395l/a/1
  3. Carried out:

    in paragraph (12), by striking , and; and

  4. Carried out:

    by striking .. and inserting , and (14) such deductible shall not apply with respect to a specified inhaler product (as defined in section 2799A–11 of the Public Health Service Act) furnished on or after January 1, 2026..

§ 1395l(a)–(c)

Start of § 1395l to (a)(9) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(a)(10)(10) (10)
with respect to rural emergency hospital services furnished on or after January 1, 2023, the amounts determined under section 1395m(x) of this title.with respect to rural emergency hospital services furnished on or after January 1, 2023, the amounts determined under section 1395m(x) of this title.
(a)Paragraph (3)(A) shall not apply to Federally qualified health center services furnished on or after the implementation date of the prospective payment system under section 1395m(o) of this title. For services furnished on or after January 1, 2022, paragraph (1)(Y) shall apply with respect to a colorectal cancer screening test regardless of the code that is billed for the establishment of a diagnosis as a result of the test, or for the removal of tissue or other matter or other procedure that is furnished in connection with, as a result of, and in the same clinical encounter as the screening test. The Secretary shall make such adjustments as may be necessary to the amounts paid as specified under paragraph (1)(S)(ii) for insulin furnished on or after July 1, 2023, through an item of durable medical equipment covered under section 1395x(n) of this title, such that the amount of coinsurance payable by an individual enrolled under this part for a month’s supply of such insulin does not exceed $35.Paragraph (3)(A) shall not apply to Federally qualified health center services furnished on or after the implementation date of the prospective payment system under section 1395m(o) of this title. For services furnished on or after January 1, 2022, paragraph (1)(Y) shall apply with respect to a colorectal cancer screening test regardless of the code that is billed for the establishment of a diagnosis as a result of the test, or for the removal of tissue or other matter or other procedure that is furnished in connection with, as a result of, and in the same clinical encounter as the screening test. The Secretary shall make such adjustments as may be necessary to the amounts paid as specified under paragraph (1)(S)(ii) for insulin furnished on or after July 1, 2023, through an item of durable medical equipment covered under section 1395x(n) of this title, such that the amount of coinsurance payable by an individual enrolled under this part for a month’s supply of such insulin does not exceed $35.
(b)(b) Deductible provision(b) Deductible provision
Before applying subsection (a) with respect to expenses incurred by an individual during any calendar year, the total amount of the expenses incurred by such individual during such year (which would, except for this subsection, constitute incurred expenses from which benefits payable under subsection (a) are determinable) shall be reduced by a deductible of $75 for calendar years before 1991, $100 for 1991 through 2004, $110 for 2005, and for a subsequent year the amount of such deductible for the previous year increased by the annual percentage increase in the monthly actuarial rate under section 1395r(a)(1) of this title ending with such subsequent year (rounded to the nearest $1); except that (1) such total amount shall not include expenses incurred for preventive services described in subparagraph (A) of section 1395x(ddd)(3) of this title that are recommended with a grade of A or B by the United States Preventive Services Task Force for any indication or population and are appropriate for the individual.,1 (2) such deductible shall not apply with respect to home health services (other than a covered osteoporosis drug (as defined in section 1395x(kk) of this title)), (3) such deductible shall not apply with respect to clinical diagnostic laboratory tests for which payment is made under this part (A) under subsection (a)(1)(D)(i) or (a)(2)(D)(i) on an assignment-related basis, or to a provider having an agreement under section 1395cc of this title, or (B) for tests furnished before January 1, 2017, on the basis of a negotiated rate determined under subsection (h)(6), (4) such deductible shall not apply to Federally qualified health center services, (5) such deductible shall not apply with respect to screening mammography (as described in section 1395x(jj) of this title), (6) such deductible shall not apply with respect to screening pap smear and screening pelvic exam (as described in section 1395x(nn) of this title), (7) such deductible shall not apply with respect to ultrasound screening for abdominal aortic aneurysm (as defined in section 1395x(bbb) of this title), (8) such deductible shall not apply with respect to colorectal cancer screening tests (as described in section 1395x(pp)(1) of this title), (9) such deductible shall not apply with respect to an initial preventive physical examination (as defined in section 1395x(ww) of this title), (10) such deductible shall not apply with respect to personalized prevention plan services (as defined in section 1395x(hhh)(1) of this title), (11) such deductible shall not apply with respect to any specified COVID–19 testing-related service described in paragraph (1) of subsection (cc) for which payment may be made under a specified outpatient payment provision described in paragraph (2) of such subsection, (12) such deductible shall not apply with respect a COVID–19 vaccine and its administration described in section 1395x(s)(10)(A) of this title, and (13) such deductible shall not apply with respect to insulin furnished on or after July 1, 2023, through an item of durable medical equipment covered under section 1395x(n) of this title.[struck: .]1 The total amount of the expenses incurred by an individual as determined under the preceding sentence shall, after the reduction specified in such sentence, be further reduced by an amount equal to the expenses incurred for the first three pints of whole blood (or equivalent quantities of packed red blood cells, as defined under regulations) furnished to the individual during the calendar year, except that such deductible for such blood shall in accordance with regulations be appropriately reduced to the extent that there has been a replacement of such blood (or equivalent quantities of packed red blood cells, as so defined); and for such purposes blood (or equivalent quantities of packed red blood cells, as so defined) furnished such individual shall be deemed replaced when the institution or other person furnishing such blood (or such equivalent quantities of packed red blood cells, as so defined) is given one pint of blood for each pint of blood (or equivalent quantities of packed red blood cells, as so defined) furnished such individual with respect to which a deduction is made under this sentence. The deductible under the previous sentence for blood or blood cells furnished an individual in a year shall be reduced to the extent that a deductible has been imposed under section 1395e(a)(2) of this title to blood or blood cells furnished the individual in the year. Paragraph (1) of the first sentence of this subsection shall apply with respect to a colorectal cancer screening test regardless of the code that is billed for the establishment of a diagnosis as a result of the test, or for the removal of tissue or other matter or other procedure that is furnished in connection with, as a result of, and in the same clinical encounter as the screening test.Before applying subsection (a) with respect to expenses incurred by an individual during any calendar year, the total amount of the expenses incurred by such individual during such year (which would, except for this subsection, constitute incurred expenses from which benefits payable under subsection (a) are determinable) shall be reduced by a deductible of $75 for calendar years before 1991, $100 for 1991 through 2004, $110 for 2005, and for a subsequent year the amount of such deductible for the previous year increased by the annual percentage increase in the monthly actuarial rate under section 1395r(a)(1) of this title ending with such subsequent year (rounded to the nearest $1); except that (1) such total amount shall not include expenses incurred for preventive services described in subparagraph (A) of section 1395x(ddd)(3) of this title that are recommended with a grade of A or B by the United States Preventive Services Task Force for any indication or population and are appropriate for the individual.,1 (2) such deductible shall not apply with respect to home health services (other than a covered osteoporosis drug (as defined in section 1395x(kk) of this title)), (3) such deductible shall not apply with respect to clinical diagnostic laboratory tests for which payment is made under this part (A) under subsection (a)(1)(D)(i) or (a)(2)(D)(i) on an assignment-related basis, or to a provider having an agreement under section 1395cc of this title, or (B) for tests furnished before January 1, 2017, on the basis of a negotiated rate determined under subsection (h)(6), (4) such deductible shall not apply to Federally qualified health center services, (5) such deductible shall not apply with respect to screening mammography (as described in section 1395x(jj) of this title), (6) such deductible shall not apply with respect to screening pap smear and screening pelvic exam (as described in section 1395x(nn) of this title), (7) such deductible shall not apply with respect to ultrasound screening for abdominal aortic aneurysm (as defined in section 1395x(bbb) of this title), (8) such deductible shall not apply with respect to colorectal cancer screening tests (as described in section 1395x(pp)(1) of this title), (9) such deductible shall not apply with respect to an initial preventive physical examination (as defined in section 1395x(ww) of this title), (10) such deductible shall not apply with respect to personalized prevention plan services (as defined in section 1395x(hhh)(1) of this title), (11) such deductible shall not apply with respect to any specified COVID–19 testing-related service described in paragraph (1) of subsection (cc) for which payment may be made under a specified outpatient payment provision described in paragraph (2) of such subsection, (12) such deductible shall not apply with respect a COVID–19 vaccine and its administration described in section 1395x(s)(10)(A) of this title, and (13) such deductible shall not apply with respect to insulin furnished on or after July 1, 2023, through an item of durable medical equipment covered under section 1395x(n) of this title[inserted: , and (14) such deductible shall not apply with respect to a specified inhaler product (as defined in section 2799A–11 of the Public Health Service Act) furnished on or after January 1, 2026].1 The total amount of the expenses incurred by an individual as determined under the preceding sentence shall, after the reduction specified in such sentence, be further reduced by an amount equal to the expenses incurred for the first three pints of whole blood (or equivalent quantities of packed red blood cells, as defined under regulations) furnished to the individual during the calendar year, except that such deductible for such blood shall in accordance with regulations be appropriately reduced to the extent that there has been a replacement of such blood (or equivalent quantities of packed red blood cells, as so defined); and for such purposes blood (or equivalent quantities of packed red blood cells, as so defined) furnished such individual shall be deemed replaced when the institution or other person furnishing such blood (or such equivalent quantities of packed red blood cells, as so defined) is given one pint of blood for each pint of blood (or equivalent quantities of packed red blood cells, as so defined) furnished such individual with respect to which a deduction is made under this sentence. The deductible under the previous sentence for blood or blood cells furnished an individual in a year shall be reduced to the extent that a deductible has been imposed under section 1395e(a)(2) of this title to blood or blood cells furnished the individual in the year. Paragraph (1) of the first sentence of this subsection shall apply with respect to a colorectal cancer screening test regardless of the code that is billed for the establishment of a diagnosis as a result of the test, or for the removal of tissue or other matter or other procedure that is furnished in connection with, as a result of, and in the same clinical encounter as the screening test.
(c)(c) Mental disorders(c) Mental disorders
(c)(1)(1) (1)
Notwithstanding any other provision of this part, with respect to expenses incurred in a calendar year in connection with the treatment of mental, psychoneurotic, and personality disorders of an individual who is not an inpatient of a hospital at the time such expenses are incurred, there shall be considered as incurred expenses for purposes of subsections (a) and (b)—Notwithstanding any other provision of this part, with respect to expenses incurred in a calendar year in connection with the treatment of mental, psychoneurotic, and personality disorders of an individual who is not an inpatient of a hospital at the time such expenses are incurred, there shall be considered as incurred expenses for purposes of subsections (a) and (b)—

§ 1395l(t)(12)Limitation on review(A)–(C)

(c)(1)(A)–(t)(11)(B) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(12)(12) Limitation on review(12) Limitation on review
There shall be no administrative or judicial review under section 1395ff of this title, 1395oo of this title, or otherwise of—There shall be no administrative or judicial review under section 1395ff of this title, 1395oo of this title, or otherwise of—
(A)(A) (A)
the development of the classification system under paragraph (2), including the establishment of groups and relative payment weights for covered OPD services, of wage adjustment factors, other adjustments[struck: ,] [struck: and ]methods described in paragraph (2)(F);the development of the classification system under paragraph (2), including the establishment of groups and relative payment weights for covered OPD services, of wage adjustment factors, other adjustments methods described in paragraph (2)(F);
(B)(B) (B)
the calculation of base amounts under paragraph (3);the calculation of base amounts under paragraph (3);
(C)(C) (C)
periodic adjustments made under paragraph (6);periodic adjustments made under paragraph (6);

Rest of § 1395l unchanged

42 U.S.C. § 1395w–102 Prescription drug benefits

+12 −3Shown
More for 42 U.S.C. § 1395w–102
Read § 1395w–102Only this section
5 changes the bill asks for here, 5 carried out
  1. Carried out:

    in paragraph (1)(A), by striking paragraphs (8) and (9) and inserting paragraphs (8), (9), and (10);

  2. Carried out:

    in paragraph (2)(A), by striking paragraphs (8) and (9) and inserting paragraphs (8), (9), and (10);

  3. Carried out:

    in paragraph (4)(A)(i), by striking paragraphs (8) and (9) and inserting paragraphs (8), (9), and (10); and

  4. Carried out:

    by adding at the end the following new paragraph:(10) Treatment of cost-sharing for specified inhaler products.— (A) No application of deductible.— For plan year 2026 and subsequent plan years, the deductible under paragraph (1) shall not apply with respect to any specified inhaler product. (B) Application of cost-sharing.— …

  5. Carried out:

    Section 1860D–2(c) of the Social Security Act (42 U.S.C. 1395w–102(c)) is amended by adding at the end the following new paragraph:(7) Treatment of cost-sharing for specified insulin products.— The coverage in provided in accordance with subsection (b)(10)..

§ 1395w–102(b)Standard prescription drug coverage(1)–(2)

Start of § 1395w–102 to (a)(5) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(b)(b) Standard prescription drug coverage(b) Standard prescription drug coverage
For purposes of this part and part C, the term “standard prescription drug coverage” means coverage of covered part D drugs that meets the following requirements:For purposes of this part and part C, the term “standard prescription drug coverage” means coverage of covered part D drugs that meets the following requirements:
(1)(1) Deductible(1) Deductible
(1)(A)(A) In general(A) In general
Subject to paragraphs (8) and ([struck: 9]), the coverage has an annual deductible—Subject to paragraphs (8)[inserted: ,] [inserted: (9), ]and ([inserted: 10]), the coverage has an annual deductible—
(1)(A)(i)(i) (i)
for 2006, that is equal to $250; orfor 2006, that is equal to $250; or
(1)(A)(ii)(ii) (ii)
for a subsequent year, that is equal to the amount specified under this paragraph for the previous year increased by the percentage specified in paragraph (6) for the year involved.for a subsequent year, that is equal to the amount specified under this paragraph for the previous year increased by the percentage specified in paragraph (6) for the year involved.
(1)(B)(B) Rounding(B) Rounding
Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.
(2)(2) Benefit structure(2) Benefit structure
(2)(A)(A) 25 percent coinsurance(A) 25 percent coinsurance
Subject to subparagraphs (C), (D), and (E) and paragraphs (8) and ([struck: 9]), the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—Subject to subparagraphs (C), (D), and (E) and paragraphs (8)[inserted: ,] [inserted: (9), ]and ([inserted: 10]), the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—
(2)(A)(i)(i) (i)
equal to 25 percent; orequal to 25 percent; or
(2)(A)(ii)(ii) (ii)
actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.

§ 1395w–102(b)(4)Protection against high out-of-pocket expenditures(A)

(b)(2)(B)–(3)(B) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(4)(4) Protection against high out-of-pocket expenditures(4) Protection against high out-of-pocket expenditures
(A)(A) In general(A) In general
(A)(i)(i) In general(i) In general
Subject to paragraphs (8) and ([struck: 9]), the coverage provides benefits, after the part D eligible individual has incurred costs (as described in subparagraph (C)) for covered part D drugs in a year equal to the annual out-of-pocket threshold specified in subparagraph (B), with cost-sharing that is equal to—Subject to paragraphs (8)[inserted: ,] [inserted: (9), ]and ([inserted: 10]), the coverage provides benefits, after the part D eligible individual has incurred costs (as described in subparagraph (C)) for covered part D drugs in a year equal to the annual out-of-pocket threshold specified in subparagraph (B), with cost-sharing that is equal to—
(A)(i)(I)(I) (I)
for a year preceding 2024, the greater of—for a year preceding 2024, the greater of—
(A)(i)(I)(aa)(aa) (aa)
a copayment of $2 for a generic drug or a preferred drug that is a multiple source drug (as defined in section 1396r–8(k)(7)(A)(i) of this title) and $5 for any other drug; ora copayment of $2 for a generic drug or a preferred drug that is a multiple source drug (as defined in section 1396r–8(k)(7)(A)(i) of this title) and $5 for any other drug; or

§ 1395w–102(b)–(c)

(b)(4)(A)(i)(I)(bb)–(9)(D)(ii)(II) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(b)(9)(D)(ii)(III)(III) (III)
an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan.an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan.
(b)(9)(E)(E) Special rule for first 3 months of 2023(E) Special rule for first 3 months of 2023
With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply.With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply.
(b)(10)(10) [inserted: Treatment of cost-sharing for specified inhaler products.—]
(b)(10)(A)(A) [inserted: No application of deductible.—]
[inserted: For plan year 2026 and subsequent plan years, the deductible under paragraph (1) shall not apply with respect to any specified inhaler product.]
(b)(10)(B)(B) [inserted: Application of cost-sharing.—]
[inserted: For plan year 2026 and subsequent plan years, the coverage provides benefits for any specified inhaler product with cost-sharing for a month’s supply that does not exceed $15.]
(b)(10)(C)(C) [inserted: Definition.—]
[inserted: For purposes of this paragraph, the term “specified inhaler product” has the meaning given such term in section 2799A–11 of the Public Health Service Act.]
(c)(c) Alternative prescription drug coverage requirements(c) Alternative prescription drug coverage requirements
A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design:A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design:
(c)(1)(1) Assuring at least actuarially equivalent coverage(1) Assuring at least actuarially equivalent coverage

§ 1395w–102(c)–(d)

(c)(1)(A)–(4) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(5)(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices
The coverage is in accordance with subsection (b)(8).The coverage is in accordance with subsection (b)(8).
(c)(6)(6) Treatment of cost-sharing for covered insulin products(6) Treatment of cost-sharing for covered insulin products
The coverage is provided in accordance with subsection (b)(9).The coverage is provided in accordance with subsection (b)(9).
(c)(7)(7) [inserted: Treatment of cost-sharing for specified insulin products.—]
[inserted: The coverage in provided in accordance with subsection (b)(10).]
(d)(d) Access to negotiated prices(d) Access to negotiated prices
(d)(1)(1) Access(1) Access
(d)(1)(A)(A) In general(A) In general
Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).

Rest of § 1395w–102 unchanged

42 U.S.C. § 1395w–114 Premium and cost-sharing subsidies for low-income individuals

+2 −2Shown
More for 42 U.S.C. § 1395w–114
Read § 1395w–114Only this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    in subparagraph (D)(iii), by adding at the end the following new sentence: For plan year 2026 and subsequent plan years, the copayment amount applicable under the preceding sentence to a month's supply of a specified inhaler product (as defined in section 1860D–2(b)(10)) dispensed to the individual may not exceed $15.; and

  2. Carried out:

    in subparagraph (E), by inserting or under section 1860D–2(b)(10) in the case of a specified inhaler product (as defined in such section) after (as defined in subparagraph (C) of such section).

§ 1395w–114(a)Income-related subsidies for certain individuals(1)–(2)

Start of § 1395w–114 to (a)(1)(D)(ii)(II)(bb) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(1)(D)(ii)(II)(cc)(cc) (cc)
for a drug not described in either item (aa) or (bb), the dollar amount applied under this clause for such a drug for the preceding plan year, increased in the manner specified in item (bb), or, if less, the copayment amount applicable to an individual under clause (iii).for a drug not described in either item (aa) or (bb), the dollar amount applied under this clause for such a drug for the preceding plan year, increased in the manner specified in item (bb), or, if less, the copayment amount applicable to an individual under clause (iii).
(1)(D)Any amount established under item (bb) or (cc) of subclause (II), that is based on an increase of $1 or $3, that is not a multiple of 5 cents or 10 cents, respectively, shall be rounded to the nearest multiple of 5 cents or 10 cents, respectively.Any amount established under item (bb) or (cc) of subclause (II), that is based on an increase of $1 or $3, that is not a multiple of 5 cents or 10 cents, respectively, shall be rounded to the nearest multiple of 5 cents or 10 cents, respectively.
(1)(D)(iii)(iii) Other individuals(iii) Other individuals
Subject to paragraph (6), in the case of an individual not described in clause (i) or (ii), the substitution for the beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title) of a copayment amount that does not exceed the copayment amount specified under section 1395w–102(b)(4)(A)(i)(I)(aa) of this title for the drug and year involved. For plan year 2023 and subsequent plan years, the copayment amount applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.Subject to paragraph (6), in the case of an individual not described in clause (i) or (ii), the substitution for the beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title) of a copayment amount that does not exceed the copayment amount specified under section 1395w–102(b)(4)(A)(i)(I)(aa) of this title for the drug and year involved. For plan year 2023 and subsequent plan years, the copayment amount applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.[inserted: For plan year 2026 and subsequent plan years, the copayment amount applicable under the preceding sentence to a month's supply of a specified inhaler product (as defined in section 1860D–2(b)(10)) dispensed to the individual may not exceed $15.]
(1)(E)(E) Elimination of cost-sharing above annual out-of-pocket threshold(E) Elimination of cost-sharing above annual out-of-pocket threshold
For a year preceding 2024, the elimination of any cost-sharing imposed under section 1395w–102(b)(4)(A) of this title or under section 1395w–102(b)(9) of this title in the case of a covered insulin product (as defined in subparagraph (C) of such section).For a year preceding 2024, the elimination of any cost-sharing imposed under section 1395w–102(b)(4)(A) of this title or under section 1395w–102(b)(9) of this title in the case of a covered insulin product (as defined in subparagraph (C) of such section)[inserted: or under section 1860D–2(b)(10) in the case of a specified inhaler product (as defined in such section)].
(2)(2) Other low-income individuals(2) Other low-income individuals
With respect to a plan year beginning before January 1, 2024, in the case of a subsidy eligible individual who is not described in paragraph (1), the individual is entitled under this section to the following:With respect to a plan year beginning before January 1, 2024, in the case of a subsidy eligible individual who is not described in paragraph (1), the individual is entitled under this section to the following:
(2)(A)(A) Sliding scale premium subsidy(A) Sliding scale premium subsidy
An income-related premium subsidy determined on a linear sliding scale ranging from 100 percent of the amount described in paragraph (1)(A) for individuals with incomes at or below 135 percent of such level to 0 percent of such amount for individuals with incomes at 150 percent of such level.An income-related premium subsidy determined on a linear sliding scale ranging from 100 percent of the amount described in paragraph (1)(A) for individuals with incomes at or below 135 percent of such level to 0 percent of such amount for individuals with incomes at 150 percent of such level.

Rest of § 1395w–114 unchanged

42 U.S.C. § 18022 Essential health benefits requirements

+1 −1Shown
More for 42 U.S.C. § 18022
Read § 18022Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1302(e)(1)(B)(i) of the Patient Protection and Affordable Care Act (42 U.S.C. 18022(e)(1)(B)(i)) is amended by inserting or 2799A–11 of the Public Health Service Act after section 2713.

§ 18022(e)Catastrophic plan(1)–(2)

Start of § 18022 to (e)(1)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(1)(B)(B) (B)
the plan provides—the plan provides—
(1)(B)(i)(i) (i)
except as provided in clause (ii), the essential health benefits determined under subsection (b), except that the plan provides no benefits for any plan year until the individual has incurred cost-sharing expenses in an amount equal to the annual limitation in effect under subsection (c)(1) for the plan year (except as provided for in section 2713); 1 andexcept as provided in clause (ii), the essential health benefits determined under subsection (b), except that the plan provides no benefits for any plan year until the individual has incurred cost-sharing expenses in an amount equal to the annual limitation in effect under subsection (c)(1) for the plan year (except as provided for in section 2713[inserted: or 2799A–11 of the Public Health Service Act]); 1 and
(1)(B)(ii)(ii) (ii)
coverage for at least three primary care visits.coverage for at least three primary care visits.
(2)(2) Individuals eligible for enrollment(2) Individuals eligible for enrollment
An individual is described in this paragraph for any plan year if the individual—An individual is described in this paragraph for any plan year if the individual—

Rest of § 18022 unchanged

Step through the changes